Mar 2 |
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call Transcript
|
Mar 1 |
Q4 2023 Capricor Therapeutics Inc Earnings Call
|
Mar 1 |
Capricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call Transcript
|
Feb 29 |
Capricor Therapeutics Inc (CAPR) Reports Encouraging Year-End Financials and Advances in DMD Therapy
|
Feb 29 |
Capricor Therapeutics GAAP EPS of -$0.02 beats by $0.18, revenue of $12.08M beats by $1.48M
|
Feb 29 |
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
Feb 29 |
Earnings Scheduled For February 29, 2024
|
Feb 28 |
Capricor Therapeutics Q4 2023 Earnings Preview
|
Feb 27 |
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
|
Feb 22 |
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
|